Trial Profile
Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Granulocyte colony-stimulating factors (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms EMEG-E-01
- 24 Jan 2020 Status changed from recruiting to completed.
- 25 Oct 2019 Planned End Date changed from 3 Jun 2019 to 13 Sep 2021.
- 08 Aug 2018 Planned End Date changed from 3 Dec 2018 to 3 Jun 2019.